Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun;33(6):567-580.
doi: 10.1007/s40263-019-00637-z.

Buprenorphine Treatment for Opioid Use Disorder: An Overview

Matisyahu Shulman  1   2 , Jonathan M Wai  3   4 , Edward V Nunes  3   4
Affiliations
Review

Buprenorphine Treatment for Opioid Use Disorder: An Overview

Matisyahu Shulman et al. CNS Drugs. 2019 Jun.

Abstract

Opioid use disorder affects over 26 million individuals worldwide. There are currently three World Health Organization-recommended and US Food and Drug Administration-approved medication treatments for opioid use disorder: the full opioid agonist methadone, the opioid partial agonist buprenorphine, and the opioid receptor antagonist naltrexone. We provide a review of the use of buprenorphine for the treatment of opioid use disorder and discuss the barriers, challenges, risks, and efficacy of buprenorphine treatment vs. other treatments. Although evidence from numerous studies has shown buprenorphine to be effective for the treatment of opioid use disorder, a majority of patients with opioid use disorder do not receive buprenorphine, or any other medical treatment. We review the different formulations of buprenorphine, including newer long-acting injectable formulations that may decrease the risk of diversion and improve adherence.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dr. Nunes has served as an investigator on clinical trials for which Reckitt Benckiser Inc. supplied suboxone, and for which Alkermes, Inc. supplied Vivitrol for study medication, and has served as a consultant without compensation on Advisory Boards to Alkermes, Inc. Drs. Shulman and Wai have no conflicts of interest to report.

References

    1. Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, Whiteford H, Leung J, Naghavi M, Griswold M, Rehm J. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Psychiatry. 2018. December 1;5(12):987–1012. - PMC - PubMed
    1. Center for Behavioral Health Statistics and Quality (CBHSQ). 2015 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016.
    1. Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Archives of general psychiatry. 2001. May 1;58(5):503–8. - PubMed
    1. World Health Organization. Department of Mental Health, Substance Abuse, World Health Organization, International Narcotics Control Board, United Nations Office on Drugs, Crime. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. World Health Organization; 2009. - PubMed
    1. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard review of psychiatry. 2015. March 1;23(2):63–75. - PubMed

Publication types

MeSH terms